Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells.
about
CixutumumabTargeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures.Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approachInsulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer.Targeted Therapy of Ewing's Sarcoma.The nuclear localization of MGF receptor in osteoblasts under mechanical stimulation.Can we unlock the potential of IGF-1R inhibition in cancer therapy?Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1RExpression and effects of inhibition of type I insulin-like growth factor receptor tyrosine kinase in mantle cell lymphoma.Inhibition of type I insulin-like growth factor receptor tyrosine kinase by picropodophyllin induces apoptosis and cell cycle arrest in T lymphoblastic leukemia/lymphoma.A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours.Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cellsInsulin-like growth factor: current concepts and new developments in cancer therapy.Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs.The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy.Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapyIGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells.The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors.Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.The role of the insulin-like growth factor 1 receptor axis in multiple myeloma.New agents for AML and MDS.Type I insulin-like growth factor receptor signaling in hematological malignancies.Past, present and future of therapies in pediatric sarcomas.The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas.Targeting the IGF-1R signaling and mechanisms for epigenetic gene silencing in human multiple myelomaMolecular-targeted agents combination therapy for cancer: developments and potentials.AKT as a therapeutic target in multiple myeloma.Association of a common genetic variant of the IGF-1 gene with event-free survival in patients with HER2-positive breast cancer.Cyproheptadine-induced myeloma cell apoptosis is associated with inhibition of the PI3K/AKT signaling.Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancerGSK3β regulates physiological migration of stem/progenitor cells via cytoskeletal rearrangement.AMPK-induced activation of Akt by AICAR is mediated by IGF-1R dependent and independent mechanisms in acute lymphoblastic leukemia.Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway.Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.Insulin-like growth factor signaling regulates developmental trajectory associated with diapause in embryos of the annual killifish Austrofundulus limnaeus.Inhibition of insulin-like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survival.
P2860
Q24609058-1CEFAF8D-4455-445F-9981-B5954E7DF00CQ33873775-0BB68156-6EB5-43D0-A6D7-3F3680731171Q33890792-8E881E54-A1D9-4419-8002-22835F45AD1EQ33925323-4DBB3B71-20D3-4327-A451-22A4397F8DA8Q34023117-5D35F6BD-B7D9-46F0-945E-4AF48B2B42CFQ34262377-CD28523B-EB4B-4929-A296-32ECC82892CAQ34323600-D7187B4E-2832-44FD-B580-DBE81054056CQ34336988-935233D9-8014-4A4B-BCB8-7212FEB614CFQ34438500-C15BF2B1-B144-402A-BFD9-B4220A94E263Q35018535-67918B5F-BD9D-49FF-A1BF-F34E75F67B81Q35285518-5C25044B-BA0E-4361-A277-4D0F03F3F2E1Q35677661-9960571C-E170-4A87-AB7D-4705A0E5A03AQ36240238-80AC0C19-B363-41F3-AC14-FA95C9747311Q37047067-8EBB5040-D5AA-48C2-BEC7-D2FBDADD5CC3Q37109225-244BA827-A5D0-46C2-BB92-E1128B484006Q37192602-8561FF4B-92ED-47E3-A252-2E4A68BC550AQ37192611-3B656DE2-FFC2-4859-8260-5166BCE3F277Q37192616-EA27C8FD-6BF1-4293-B567-9B584F3E1CABQ37271044-9070F08E-BB20-4DEC-B136-DFF9ABF1F27DQ37279733-DD0CFCBE-D025-4062-B8DB-F3368454366EQ37349748-5A351B31-03E6-4833-9084-620F172F28B5Q37398728-17B2CCDA-C981-4A9E-966C-A258D4D8113CQ37474602-260E1F83-D54F-4DA8-A7A3-7D4B859BD257Q37702186-DF2FE806-F10B-404C-AAD2-59C7E0F8556DQ37725915-FD0B678F-241F-43C2-941C-3DD8EEEF1611Q37870754-60C91783-012B-482B-B062-0F55F40CDE4AQ37986142-055F1B8F-0A49-484E-879B-E505CCDF6E55Q38104670-4391D105-38FA-4405-8588-5ACC52F4F1E4Q38218256-B4E50C56-843A-41A0-B7C4-3344A21D2FE6Q38399478-BBEDB382-9381-47C9-A877-5DAE47E494FAQ39096402-A8DDE329-BB4A-46F9-9D1F-9079A872DB0CQ39140763-C47ACF55-64A0-45E6-BD2F-970407B676ACQ39498749-4B260BFB-2603-4E8A-B249-127CB7CB2A00Q39652396-2F7EFFAA-9365-47A7-B4B5-CCCE073FB45CQ40117414-4F665CBA-EE2A-4FCA-9554-9041CA3797B9Q40154931-BFEF2665-4E42-4C71-BC7C-C5F74C1168D6Q46364420-9D9A88D3-323C-469B-B5C2-465B31994867Q54976722-BC40FE91-7A45-414B-8BE2-5E439E81EB21
P2860
Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Synergy between an IGF-1R anti ...... growth in hematopoietic cells.
@en
type
label
Synergy between an IGF-1R anti ...... growth in hematopoietic cells.
@en
prefLabel
Synergy between an IGF-1R anti ...... growth in hematopoietic cells.
@en
P2093
P2860
P356
P1433
P1476
Synergy between an IGF-1R anti ...... growth in hematopoietic cells
@en
P2093
Bertrand FE
Chappell WH
Shelton JG
Steelman LS
P2860
P2888
P304
P356
10.1038/SJ.LEU.2404217
P577
2006-04-27T00:00:00Z
P5875
P6179
1007458247